The effectiveness of R-Pharm’s developments was discussed at the First International Infectious Diseases Forum


The First International Infectious Diseases Forum has opened in Moscow at the congress center of the I.M. Sechenov First Moscow State Medical University (Sechenov University). The general partner of the forum was R-Pharm group of companies. The large-scale forum brought together various medical professionals, including infectious disease specialists, pulmonologists, cardiologists, and endocrinologists, who shared their views on the effectiveness of the latest therapeutic approaches, as well as the accumulated experience in the treatment of infectious diseases of various groups, including during the COVID-19 pandemic.

One of the most important sessions of the International Infectious Diseases Forum was the satellite symposium “Comorbid Patient with COVID-19: Teamwork where Time Makes a Difference”, organized by R-Pharm Group of companies, moderated by Vladimir Chulanov, Chief consultant in infectious Diseases of the Ministry of Health of the Russian Federation. Within the framework of a multidisciplinary discussion panel, specialists of various profiles from Russian regions, including anesthesiologists, rheumatologists, cardiologists, infectious disease specialists, pulmonologists, and endocrinologists discussed the possibilities of modern therapy, in particular, interleukin-1 and interleukin-6 inhibitors, for counteracting coronavirus infection.

In her speech, Anna Simakova, Chief consultant in infectious Diseases of the Ministry of Health of Primorsky Krai, noted that proactive therapy with interleukin-6 inhibitors inhibits systemic inflammation and prevents a cytokine storm, reducing the risk of multiple organ failure and death.

In his turn, Pavel Novikov, Candidate of Sciences, Head of the Rheumatology Department of Tareev Clinic of Rheumatology, Nephrology and Occupational Pathology, stressed that interleukin-1 inhibitors, which are used in the treatment of both rheumatoid arthritis and monogenic autoinflammatory diseases, can also be used to prevent the development of inflammation in COVID-19.

The effectiveness of proactive therapy with interleukin inhibitors was also stated by other participants in the discussion: Nikita Lomakin, Chief Cardiologist of the Presidential Administration of the Russian Federation, Natalia Kostina, Chief consultant pulmonologist of the Voronezh Region Health Department, Tatiana Markova, Head of the Endocrinology Department of Moscow City Hospital No. 52, and Vadim Soldatov, resuscitator of the Pskov Regional Clinical Hospital.


Exit mobile version